Literature DB >> 1533595

Long-term multicentre trial in chronic nonspecific lung disease: methodology and baseline assessment in adult patients. Dutch CNSLD Study Group.

P L Brand1, H A Kerstjens, D S Postma, P J Sterk, P H Quanjer, H J Sluiter, J H Dijkman, C L van Herwaarden, C Hilvering, H M Jansen.   

Abstract

Airways obstruction and airways hyperresponsiveness are two dominant features in patients with chronic nonspecific lung disease (asthma and chronic obstructive pulmonary disease (COPD)). We set up a study to determine whether long-term (3 yrs) therapeutic intervention directed at airways obstruction and hyperresponsiveness is superior to one directed at airways obstruction alone. Patients were selected on functional criteria (age, baseline forced expiratory volume in one second (FEV1), and airways hyperresponsiveness) and, furthermore, extensively characterized by history, smoking habits, allergy, reversibility of airways obstruction and quality of life. The methodology and practical problems of setting up this large multicentre study are outlined, together with an analysis of baseline data. Standardization of methods and techniques and recruitment of patients required much effort, recruitment taking about twice as long as expected. A 3 month feasibility study allowed us to eliminate minor problems in the protocol. Over a 16 month period, 274 adult patients (18-60 yrs) from the out-patient clinics of six university centres entered the study; 99 met the diagnostic criteria for asthma, 51 for COPD, 88 for asthmatic bronchitis, and 36 could not be classified. Their mean (SD) FEV1% pred was 65.1 (15.2)%. Their geometric mean provoking concentration of histamine producing a 20% fall in FEV1 (PC20 histamine) was 0.28 mg.ml-1. In a multiple regression analysis, more severe airways hyperresponsiveness was associated with lower prechallenge FEV1% pred (p less than 0.0001), higher pack-years of smoking (p = 0.0099), blood eosinophil count (p = 0.0004), skin test reactivity (p = 0.0047) and with female sex (p = 0.0302). We conclude that setting up long-term multicentre trials in chronic nonspecific lung disease (CNSLD) is feasible and that these may offer valuable information on treatment and outcome of the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533595

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Anticholinergic agents for chronic asthma in adults.

Authors:  M Westby; M Benson; P Gibson
Journal:  Cochrane Database Syst Rev       Date:  2004

2.  Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.

Authors:  H A Kerstjens; P L Brand; P H Quanjer; B A van der Bruggen-Bogaarts; G H Koëter; D S Postma
Journal:  Thorax       Date:  1993-07       Impact factor: 9.139

3.  Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group.

Authors:  H A Kerstjens; P L Brand; P M de Jong; G H Koëter; D S Postma
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

4.  Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group.

Authors:  P L Brand; P H Quanjer; D S Postma; H A Kerstjens; G H Koëter; P N Dekhuijzen; H J Sluiter
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

5.  The practical application and interpretation of simple lung function tests in cystic fibrosis.

Authors:  P L Brand; C K van der Ent
Journal:  J R Soc Med       Date:  1999       Impact factor: 18.000

6.  Cell surface antigen expression by peripheral blood monocytes in allergic asthma: results of 2.5 years therapy with inhaled beclomethasone dipropionate.

Authors:  W A Slieker; P T Hal; J M Wijkhuijs; J P Hopstaken-Broos; J A Noordhoek; S E Overbeek; P G Mulder; D S Postma; H C Hoogsteden
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.